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Introduction
The case report that this clinical commentary accompanies
(Vichi et al. 2021) describes the diagnosis and treatment of a
2-year-old horse with cutaneous papillomatosis lesions,
attributed to Equus caballus papillomavirus 2 (EcPV2)
infection, and concurrent cutaneous habronemiasis. The
additional pathology caused by the presence of
Habronematidae larvae necessitated surgical removal of the
lesions. Without this coinfection, the papillomavirus infection
and lesions could have progressed in several ways.
The number of known papillomaviruses is increasing for
many species, including equids, as is the range of pathologies
in which they are implicated. This article summarises known
presentations of papillomavirus-associated infections in equids
and outlines the underlying host-viral biology.z
Progress in papillomavirus discovery
Papillomavirus (PV) infections may be latent, subclinical or
result in lesion development. Active infections may cause self-
resolving benign proliferative lesions, more severe or persistent
benign disease, or malignant cancers (Fig 1). To date, nine
Equus caballus papillomaviruses (EcPV1 to 9) and two asinine
papillomaviruses (EaPV1 and 2) have been identified
(Papillomavirus Episteme). Additionally, bovine papillomavirus
(BPV) types 1, 2 (Chambers et al. 2003) and 13 (Lunardi et al.
2013) infect horses and donkeys and cause equine sarcoids,
in an unusual example of a cross-species infection by this
host-specific family of viruses.
In humans, 225 papillomaviruses (HPVs) have been
identified (Papillomavirus Episteme), of which at least 14 can
cause cancer with metastatic potential (high-risk HPVs
(hrHPVs)) (World Health Organization 2020). An infectious
cause of human cervical cancer was first suspected from the
1950s onwards, and hrHPVs 16 and 18 were characterised as
causes of cervical cancer in the 1980s (D€urst et al. 1983;
Boshart et al. 1984), a discovery for which Harald zur Hausen
was awarded a Nobel Prize (Nobel Prize 2008). It is now
known that hrHPVs are the cause of almost all cases of
cervical cancer, as well as a significant proportion of other
anogenital cancers and approximately 25% of head and
neck cancers (de Martel et al. 2017). Moreover, hrHPVs are
implicated in over 5% of human cancers worldwide (Berman
and Schiller 2017). Given the much lower numbers of PVs so
far discovered in veterinary species, for example, 23 in dogs
and 27 in cattle (Papillomavirus Episteme), it seems there are
many more veterinary PVs to discover, both of low and high
clinical significance. Additionally, already known veterinary
PVs could become newly implicated in pathological
conditions.
There has been a considerable increase in the number of
known equine-infecting PVs in the last decade, prior to which
only EcPV1 (Ghim et al. 2004) and BPV1 and BPV2 (Chambers
et al. 2003) were fully characterised. PVs were previously
suspected to be involved in genital papillomas and
carcinomas and aural plaques, but EcPV2 and EcPV3,
respectively, were not fully characterised from samples of
these lesions until 2011 (Lange et al. 2011). EcPVs 4 to 7 were
first reported in 2013 (Lange et al. 2013), EcPV8 in 2018 (Linder
et al. 2018) and EcPV9 in 2019 (Li et al. 2019). In 2013, BPV13
was linked with sarcoids after being detected in samples in
Brazil (Lunardi et al. 2013). Equus asinus papillomavirus 1
(EaPV1) was discovered in 2014 in Asinara white donkeys with
no proliferative lesions and appears to have low
pathogenicity (Lecis et al. 2014), whereas EcPV8 was
discovered in horses with severe, generalised papillomatosis
(Linder et al. 2018). Furthermore, EcPV2 has recently been
associated with an increasing range of squamous cell
carcinomas (SCCs), its DNA having been detected in a
subset of SCCs of the stomach (Alloway et al. 2020) and
head (Sykora et al. 2017) as well as of the genitalia.
Papillomaviruses in benign proliferative disease
Most PVs are strictly epitheliotrophic, infecting dermal
keratinocytes or squamous epithelium. A subset of PVs also
infects mesenchymal cells; for example, BPV1, BPV2 and
BPV13 infect and transform dermal fibroblasts as well as
keratinocytes (Bocaneti et al. 2016). The life cycle of PVs is
linked to epithelial differentiation, a strategy that enables
virions to be shed during desquamation and helps the virus
escape the immune response (Fig 2). PVs have a double
stranded circular DNA genome, encoding early (E) genes
involved in viral genome replication and oncogenesis, and
late (L) genes which encode the capsid proteins (Fig 3). The
early genes are expressed in deeper tissue layers and the
late genes only more superficially (Nasir and Campo 2008).
Papillomavirus infections are productive, with virions shed
by infected hosts, in classic papillomatosis. An example is
EcPV1-associated “warts” which mostly occur on the face
and distal limbs of young horses. These typically
spontaneously regress within a few weeks, when the host
clears the infection and becomes immune to reinfection
(Dong et al. 2017). Benign dermal fibropapillomas in cattle
induced by BPV1 and BPV2 follow the same course, but the
growths include proliferating fibroblasts as well as
keratinocytes. In a minority of cases, for example if the host is
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Fig 1: Possible outcomes for Equus caballus papillomaviral (EcPV) infections. NB more than one state may exist within a host, for















Fig 2: Schematic diagram of the productive life cycle of papillomaviruses (Created with BioRender.com).
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immunocompromised, these infections are not cleared and
the lesions become more severe and widespread (Turk et al.
2005). As discussed in the case report, co-infection with other
pathogens may influence viral survival and pathogenesis.
Some equine PV infections involve persistent productive
infections and lesions, for example, chronic genital
papillomas associated with EcPV2 infection (Knight et al.
2011). Equine aural plaques are thought to be caused by
EcPV3, EcPV4 and EcPV6, and co-infections with these viral
types and with EcPV1 and EcPV5 appear common (Mira
et al. 2018). As mentioned in the case report, the presence of
one skin pathogen may aid invasion by another. Although
not usually clinically significant, aural plaques typically do not
regress and the finding of PV-like structures in the lesions by
electron microscopy (Fairley and Haines 1992) suggests virion
production. EcPV8 was reported to cause thousands of
widespread coalescing hyperkeratotic papules and plaques,
particularly on the trunk, in three horses. The lesions persisted
for over a year in all three, after which one was euthanased
and the others were lost to follow-up. Viral capsid protein was
detected in the lesions, suggesting a productive infection in
these cases too (Linder et al. 2018).
Papillomaviruses in invasive/metastatic disease
EcPV2 is being increasingly associated with some SCCs of the
horse. Additionally, an aural SCC containing EcPV4 DNA was
reported in an aged horse with multiple aural plaques
(Peters-Kennedy et al. 2020) and a horse with EcPV8-
containing lesions was reported to have multiple SCCs as well
as extensive papillomas in the inguinal region (Peters-
Kennedy et al. 2019).
Integration of the PV genome into the host genome is a
dead end for the virus because the infection becomes
nonproductive. However, it is an important step in hrHPV-
induced oncogenesis and is seen in most, although not all,
human cervical SCCs (Groves and Coleman 2015). It is also
possible to have nonproductive infections in which the viral
genome is maintained in its circular episomal form, as occurs
in latency (De Leo et al. 2020). In equine sarcoids, the BPV
genome appears to remain episomal and not to integrate,
meaning expression of the viral genome alone is able to
transform cells (Amtmann et al. 1980). Equids have
traditionally been considered dead end hosts of BPV
because infective virions have not been isolated from equine
sarcoids as they can be from bovine papillomas (Hainisch
et al. 2017). However, there are reports and evidence of
apparent equid-equid transmission and sarcoid outbreaks
(Ragland et al. 1966; Reid et al. 1994; Nasir and Campo 2008)
and of equid-adapted BPV1 variants (Nasir et al. 2007). It is
unclear how virions could be produced from fibroblasts, given
virion production is linked to epithelial differentiation, and
sarcoids are primarily tumours of fibroblasts with variable
epidermal involvement (Martens et al. 2000). However, BPV1
infection has been found in the epidermis as well as the
dermis of sarcoids, viral L1 capsid protein has been detected
in sarcoid epidermis (Brandt et al. 2011), and approximately
half of tested sarcoids are positive on an assay which detects
BPV DNA complexed to L1 capsid protein (Brandt et al. 2008),
suggesting at least some equids may be able to shed BPV1
and BPV2.
The case report unusually identified EcPV2 in cutaneous
lesions on the face (Vichi et al. 2021). EcPV2 is usually
associated with lesions in the genital area and more recently
of the nasal and oral cavities (Sykora et al. 2017). However, it
is possible that some cases of facial warts presumed to be
caused by EcPV1 could contain EcPV2. EcPV2 DNA has been




























Fig 3: Schematic diagram of a papillomaviral genome, showing the open reading frame and function of each gene and the area
disrupted if the viral genome integrates into the host genome.
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precancerous lesions and SCCs (Bogaert et al. 2012).
However, it is found in a much higher proportion of samples
from SCCs than from healthy animals, suggesting it is an
“oncogenic rather than a commensal virus” (summarised in
Sykora and Brandt 2017). Additionally, an in situ hybridisation
study using probes for EcPV2 detected viral material in 80–
100% of neoplastic cells in a subset of genital SCCs, and in
vessels of regional lymph nodes and metastases, providing
stronger evidence that this virus is causative for SCCs than
PCR positivity alone (Zhu et al. 2015). There is also some
evidence that EcPV2 may integrate into the host genome, as
hrHPVs do. In a qPCR (quantitative PCR) study, a subset of
EcPV2-positive equine genital SCCs contained more copies
of the viral E6 oncogene than the regulatory E2 gene, which
is disrupted by integration (Fig 3), per host cell (Sykora et al.
2017).
Papillomavirus transmission
The anatomical distribution of many PV-induced diseases is
suggestive of direct/fomite transmission. For example, EcPV1
lesions mostly occur on the face, and cattle (fibro)papillomas
are often on the head and udder. PVs are nonenveloped
viruses, resistant to freezing and desiccation (Roden et al.
1997), and may therefore persist in the environment for some
time. Virions infect new hosts via abrasions as they cannot
invade intact epithelium.
It is thought, although not yet proven, that EcPVs
implicated in aural plaques are transmitted by flying insects,
such as black flies (Simulium spp.), which are often seen in
horses’ ears (Fairley et al. 2014). The principle of flying insects
acting as mechanical vectors for PVs has been
experimentally proven in rabbits (Dalmat 1958). The
anatomical distribution of sarcoids is also suggestive of an
insect vector, and BPV1 and BPV2 DNA has been found on
UK biting and nonbiting flies (Finlay et al. 2009). However,
infective BPV virions have not been detected on flies to date.
Transmission mechanisms of other EcPVs to other
anatomical sites are unclear. HPVs causing tumours of the
head, neck and genitalia in humans are considered to be
primarily sexually transmitted, but numerous other routes, both
horizontal and vertical, have been proposed (Tumban 2019;
Mchome et al. 2021). BPV1 and BPV2 DNA has been
detected in the blood and semen of healthy equines (Silva
et al. 2014), EcPV2 in smegma (Sykora et al. 2017) and EcPV9
in semen (Li et al. 2019). Additionally, given EcPV2 has now
been found in gastric SCCs (Alloway et al. 2020) and SCCs of
the equine head including of the larynx and guttural pouch
(Hibi et al. 2019), there are multiple potential transmission
mechanisms.
Vaccination
Effective prophylactic PV vaccinations have been
developed for human patients, but post-exposure
vaccination does not appear effective. HPV vaccines
contain virus-like particles (VLP) which are empty viral capsid
protein shells. Over 90% efficacy against persistent infections
of HPV 16 and 18 has been demonstrated, and the vaccines
also appear to offer cross-protection against similar HPV types
(Cutts et al. 2007). BPV1 VLP vaccines have been shown to
be safe and immunogenic in horses (Hainisch et al. 2012),
and to protect horses from an experimental BPV1 or BPV2
challenge (Hainisch et al. 2017). Given that it may be
possible to protect horses from PV-associated diseases, further
research into the number of PVs affecting the horse, and the
range of diseases they cause, is warranted. The potential
market for such vaccinations should also be explored.
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